Companies / DXB

DIMERIX LIMITED

ASX:DXBPharmaceuticals, Biotechnology & Life Sciences
600.4M shares on issueASX (delayed) · as of 28 July 2026$0.24price · delayed$150.1Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; share count grew 9% in 24 months

Cash runway0.7 quarters of funding
Share-count growth (24m)9.0%
Raise cadence (24m)0 cash raises
Options & rights overhang2.0% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

DIMERIX LIMITED's ordinary share count was 600M as of October 2025, a 9.0% increase since July 2024. The company did not raise capital by placements, rights issues or similar during the most recent 24-month window. Options and rights on issue could convert into 12M new shares, equal to 2.0% of the current share count, with 0% currently in the money. At the March 2026 quarter DIMERIX reported A$9.5M in available cash, reported as covering 0.7 quarters at recent spending levels. There are no proposed securities issues (Appendix 3B) currently pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
2.0%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
0.7 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 600.4M per ASX (delayed) (28 July 2026).
566.8M579.1M591.5MDec 24Sept 25July 26

Cash runway

0.7 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$9.5M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
12 Dec 20253G · unquotedDXB : ORDINARY FULLY PAID600.4MAppendix 3G
22 Oct 20252A · quoted issueDXB : ORDINARY FULLY PAID600.4MAppendix 2A
12 Aug 20252A · quoted issueDXB : ORDINARY FULLY PAID600.2MAppendix 2A
1 July 20252A · quoted issueDXB : ORDINARY FULLY PAID600.1MAppendix 2A
27 June 20252A · quoted issueDXB : ORDINARY FULLY PAID598.5MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

2.0%
Total overhang · of current shares
0.0%
In the money · at current price
11.9M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
12 Dec 2025Sonia PoliOther633k300k$96k3Y notice
12 Dec 2025Hugh AlsopOther—300k$96k3Y notice
12 Dec 2025Mark DiamondOther—300k$96k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

26 July 2026Dimerix to Present at TechKnow Invest Conference 2026
22 July 2026$PUS Patent Granted for Dimerix New Asset DMX-652
16 July 2026Dimerix Investor Webinar
16 July 2026$PDimerix Expands Pipeline with Acquisition of Phase 2 Asset
16 July 2026$PDimerix Non-Dilutive Funding Builds Pipeline, Boosts Runway
14 July 2026$PTrading Halt
8 July 2026$PDMX-200 Available To Patients Via Post-Trial Access Pathways
16 June 2026Dimerix Investor Webinar
16 June 2026$PDimerix Licenses DMX200 to Everest for China and Asia Region
14 June 2026$PTrading Halt
29 Apr 2026$PDimerix Quarterly Activities Report and Appendix 4C
28 Apr 2026Dimerix Releases Investor Presentation and Video Recording
27 Apr 2026$PACTION3 Statistical Review Complete
9 Apr 2026Dimerix Singapore Investor Briefing
15 Mar 2026Dimerix Presents at Euroz Hartleys Institutional Conference
15 Mar 2026$PDimerix to Conduct Review of ACTION3 Statistical Assumptions
9 Mar 2026$PDimerix Phase 3 Trial Last Patient Receives First Dose
3 Mar 2026Dimerix Invitation to Perth and Singapore Investor Briefings
26 Feb 2026Dimerix Presents at Oppenheimer Life Sciences Conference
25 Feb 2026$PAppendix 4D and Half Year Financial Report

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.